Skip Navigation

Search By:

XX-XXX

Refine by:

14 Clinical Trials Found

Enrolling

Pilot Study to Identify Transcriptional Targets of Vitamin D in patients with Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.

This partially randomized pilot early phase I trial studies the transcriptional targets of vitamin D in patients with stage I-III colon cancer or colon cancer that has spread to the liver and can be removed by surgery who are receiving preoperative cholecalciferol. The vitamin D receptor is found in colon cancer cells. When vitamin D binds to the receptor in the cancer cells, it may stop cancer...

  • Phase: Feasibility / Pilot
  • Trial ID: NCT02172651

Enrolling

"FORCE: Focus on Reducing Dose-Limiting Toxicities in Colon Cancer with Resistance Exercise"

FORCE is a randomized home-based resistance training / strength training (RT) intervention study for Stage II and III colon cancer patients undergoing chemotherapy. Participants will be 180 newly diagnosed Stage II and III colon cancer patients from Kaiser Permanente of Northern California (KPNC), the Penn State Cancer Institute (PSCI), and the Dana Farber Cancer Institute (DFCI). The intervention...

  • Phase: Not Applicable
  • Trial ID: NCT03291951

Enrolling

RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR

This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor...

  • Phase: III
  • Trial ID: NCT02912559

Enrolling

"A Phase 2 Study of Dabrafenib and Trametinib in Combination with PDR001 in patients with BRAFV600E metastatic colorectal cancer"

This phase II trial studies the side effects and how well dabrafenib, trametinib, and spartalizumab work in treating patients with BRAFV600E mutant colorectal cancer that has spread to other places in the body. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as spartalizumab, may...

  • Phase: II
  • Trial ID: NCT03668431

Enrolling

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC),...

  • Phase: I
  • Trial ID: NCT03170960

Enrolling

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants with Relapsed/Refractory Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed / refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).

  • Phase: I
  • Trial ID: NCT03634982

Enrolling

MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the...

  • Phase: II
  • Trial ID: NCT03043313

Enrolling

A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors.

This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors....

  • Phase: I
  • Trial ID: NCT02675946

Not Enrolling

"An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients with Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C"

The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and / or recommended phase 2 dose (RP2D) and schedule.

  • Phase: I
  • Trial ID: NCT03449030